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Abstract
Background: Long-acting injectable antipsychotics (LAIs) may be a suitable therapeutic option for those patients in earlier 
stages of psychosis to avoid relapses and disease progression. Despite that, there is a lack of evidence in the literature 
regarding the use of LAIs in this profile of patients.
Methods: This is a retrospective cohort analysis to assess the efficacy, tolerability, and pattern of use of palmitate paliperidone 
long-acting injectable (PPLAI) formulations (1- and 3-month doses) compared to oral paliperidone/risperidone in patients 
with a nonaffective first episode of psychosis (FEP) over 12 months of follow-up. Relevant sociodemographic and clinical 
information were assessed, as well as main clinical scales: Positive and Negative Syndrome Scale, Personal and Social 
Performance Scale, and Clinical Global Impression Scale Improvement and Severity measures.
Results: The study included 48 patients, 16 per arm, who were aged 20–50 years and had an FEP. Significant improvements 
were registered for all treatment groups. Despite that, patients receiving PPLAI 1- and 3-month formulations obtained greater 
improvements than those in the oral group in the main domains assessed (P <  .001). We found no statistically significant 
differences in hospitalizations between groups. Side effects were presented in 24% of patients. A trend towards reducing 
antipsychotic doses was observed in 43.8% of patients to achieve the minimum effective dose and avoid the occurrence of 
side effects.
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Conclusions: To our knowledge, this is the first study assessing the use of palmitate paliperidone long-acting formulations 
versus oral risperidone or paliperidone in FEP. Treatment with PPLAI formulations seems to be an effective therapeutic choice 
at earlier stages of the disease.
Keywords:  First episode psychosis, long-acting injectable antipsychotics, paliperidone, recent-onset psychosis, risperidone, 
schizophrenia spectrum disorders
Introduction
Schizophrenia includes some severe, chronic, and enduring dis-
eases characterized by the presence of relapses and remission 
periods (Robinson et al., 1999). It is among the leading causes 
of disability worldwide and presents a substantial economic 
burden, with an annual estimated cost ranging from US $94 mil-
lion to US $102 billion (Chong et al., 2016). When considering the 
debut of the disease, early intervention becomes a crucial period 
to avoid subsequent relapses and, thus, the progression of the 
disease (Birchwood et al., 1998). Up to 50% of patients with a first 
episode of psychosis (FEP) have incomplete remission of clinical 
symptoms, which are directly associated with the presence of 
long-term deficits in cognitive abilities, social functioning, and 
quality of life (Huber et al., 2008). Lack of insight and poor medi-
cation compliance have been widely described as 2 of the most 
important predictors associated with relapse and hospital re-
admissions (Chen et al., 2005; Novick et al., 2009). Nonadherence 
to antipsychotic treatment has been established as 1 of the best 
predictors of relapse in patients with psychosis (Karson et al., 
2016; Mayoral-van Son et  al., 2016; Hui et  al., 2018). Moreover, 
the risk of relapse following a psychotic debut is estimated at 
around 77% within the first year and up to 90% in the following 
2 years (Zipursky et al., 2013).
Failure to achieve remission of symptoms has been associ-
ated with the chronicity of the disease and persistent negative 
symptoms and functional deficits, which are crucial to achieving 
psychosocial recovery (Schooler, 2006). Chronicity has also been 
associated with the existence of frequent relapses, a higher 
burden of principal careers, an impact on direct and indirect 
costs of the disease, and poorer long-term course outcomes, 
including those directly associated with the daily psychosocial 
functioning of patients with an FEP (Álvarez-Jiménez et  al., 
2012b; Mayoral-van Son et al., 2019). Hence, functional recovery 
remains the cornerstone in managing and treating patients with 
an FEP (Robinson et al., 2004). Accordingly, the development of 
new therapeutic interventions has been focused on assessing 
the compliance and the efficacy of these treatments in order to 
provide better clinical and functional outcomes.
Although the effectiveness of current antipsychotic drugs for 
managing positive symptoms in schizophrenia is well-known, 
acute psychotic exacerbations are common in this profile of 
patients (Robinson et al., 1999; Emsley et al., 2013). Moreover, pa-
tients’ responses to antipsychotic treatment seem to decrease 
from the FEP to progressive illness relapses (Jäger et al., 2007; 
Takeuchi et al., 2019), and are associated with the presence of 
residual symptoms, hindering the goal of achieving functional 
recovery (Karson et al., 2016; Zipursky et al., 2018).
Over recent years, new antipsychotic formulations, such as 
long-acting injectable atypical antipsychotics (LAI-APs), have 
emerged as promising therapeutic choices. LAI-APs represent 
a suitable option for those patients presenting with an FEP, as 
they not only have the comfort of at least a single month/tri-
mester dose, but also have improved treatment adherence. For 
that reason, and despite clinical guidelines not recommending 
LAI-AP formulations as a first-line treatment in psychosis, this 
therapeutic approach may represent a suitable option for those 
patients at earlier stages of the disease presenting with a lack of 
treatment adherence. As a result, some authors have proposed 
the use of LAI-AP formulations as the first line of treatment in 
the early stages of the disease, to avoiding the risks of relapse 
and resistance to drug treatments (Heres et al., 2014; Abdel-Baki 
et al., 2019; Salgueiro and Segarra, 2019).
To this day, there is scarce evidence in the literature re-
garding the use of LAI-APs as a first-choice line of treatment in 
patients with an FEP. The aim of this study was to evaluate the 
efficacy, tolerability, and patterns of use of long-acting injectable 
paliperidone palmitate formulations (PPLAI) compared to oral 
antipsychotic treatment in patients with an FEP.
Methods
We conducted a retrospective, observational, naturalistic, 
12-month study to assess the efficacy and tolerability of PPLAI 
formulations (1- and 3-month doses) compared to analogue 
oral antipsychotic formulations in a cohort of patients with 
nonaffective FEP. We defined oral antipsychotic treatment as the 
prescription of oral risperidone or paliperidone for comparison 
with PPLAI formulations, due to their similar pharmacological 
profiles.
The study population consisted of patients with an FEP 
who were taking oral risperidone or paliperidone or PPLAI 
Significance Statement
This retrospective naturalistic cohort study examines the efficacy, tolerability, and patterns of use of oral and long-acting (1- and 
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context of an intervention program for a first episode of psychosis, we present evidence of real-world data of patients supporting 
the use of lower doses of antipsychotics than those frequently reported in the literature.
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formulations between May 2014 and December 2018. Patients 
from both groups were followed up through the First Episode 
Psychosis Intervention Program (CRUPEP Program) developed in 
2004 at the Cruces University Hospital (Bilbao, Spain). The pro-
grammed frequency of outpatient visits was based on clinical 
conditions according to the protocolized CRUPEP Program, with 
minimum monthly assistance. Rehospitalization and emergency 
room attendance within 1 year of an antipsychotic medical pre-
scription was also reviewed. Rehospitalization was indicated if 
the patient presented with a relapse of clinical symptoms or de-
teriorated functioning (Lehman et al., 2004).
Retrospective data were retrieved from the integrated elec-
tronic medical record system from the Basque Country Health 
Service. Relevant clinical and sociodemographic data and the 
number of resources used during the 12  months of follow-up 
(number of consultations carried out in the CRUPEP Program, 
hospitalizations, and emergency room attendances related to 
illness) were retrieved. Antipsychotic treatment was prescribed 
according to CRUPEP Program rationale, tailoring it to the spe-
cific necessities of each patient. We retrieved data from clinical 
scales evaluated as protocol, including the Positive and Negative 
Syndrome Scale (PANSS; Kay et al., 1987), the Personal and Social 
Performance Scale (PSP; Morosini et al., 2000), and the Clinical 
Global Impression Improvement and Severity scales (CGI-I and 
CGI-S; Busner and Targum, 2007).
The inclusion criteria for the study were being older than 
18 years old and having a documented diagnosis of nonaffective 
FEP. The exclusion criteria for this study included having ir-
regular control visits, having documented nonadherence to 
antipsychotic treatment, and withdrawal from follow-up con-
sultations. Ethics committee approval was obtained for the 
development of this study. This research was performed in ac-
cordance with the ethical standards laid down at the Declaration 
of Helsinki. Conforming to international standards for research 
ethics, this study was approved by the local institutional ethical 
review committee.
Statistical Analysis
Demographic and clinical baseline characteristics were sum-
marized using descriptive statistics and were analyzed using 
a t-test for nominal variables or a Mann-Whitney U test. For 
categorical variables, the X2 test was used. Friedman’s test was 
used to test the significance of the change from baseline to the 
endpoint. Changes in clinical scales such as the PANSS and PSP 
were analyzed using the Wilcoxon signed-rank test and a paired 
t-test, respectively. Changes in the ordinal measures of CGI-S 
and CGI-I were analyzed using the Wilcoxon signed-rank test 
and a paired t-test. The level of statistical significance was set at 




A total of 221 FEP patient records (both affective and nonaffective) 
were analyzed from the study time frame (2014–2018). Of them, 
48 patients fulfilled the inclusion criteria of 12 months of treat-
ment with oral risperidone or paliperidone monotherapy or 
with a 1-month or 3-month PPLAI monotherapy formulation, 
and patients’ clinical histories were retrieved for analysis. The 
flowchart for sample selection is presented in Figure 1.
Of the 48 included patients, 16 received oral risperidone 
or paliperidone, 16 received a 1-month dose of injectable 
paliperidone palmitate (PPLAI-1M), and 16 received a 3-month 
dose of injectable paliperidone palmitate (PPLAI-3M). Among 
them, 65% of all included patients were antipsychotic naïve 
until they started on paliperidone. For the patients who were 
not antipsychotic naïve, the median time from the debut of 
the disease to initiation of antipsychotic treatment with oral 
risperidone/paliperidone was 13 weeks (interquartile range, 
2.65–19.5). Overall, patients did not present significant differ-
ences among the main sociodemographic variables assessed 
at baseline. Whereas the oral treatment group showed a higher 
proportion of women (50%), the difference did not reach statis-
tical significance. In Table 1, we present the demographic base-
line characteristics of all participants included in the study. 
Among other relevant sociodemographic variables, a substan-
tial percentage of patients lived with their family of origin (58%) 
and were unemployed (62.5%), with these characteristics most 
pronounced in the PPLAI-1M and PPLAI-3M groups. At the end of 
the study, most patients had a diagnosis of schizophrenia (85%). 
Drug use was reported in 58% of patients, with cannabis (46%) 
being the most prevalent substance used among patients in the 
PPLAI-1M group, followed by stimulants (25%).
Clinical Response
During the 12-month study period, the main domains assessed 
through the PANSS scale decreased in both the PPLAI-1M and 
oral groups. More specifically, the PPLAI-1M patients showed a 
significant reduction in scores on the PANSS positive subscale 
compared to those receiving oral risperidone or paliperidone 
(z  =  -4.708; P  <  .001). The mean changes from baseline to the 
final endpoint on the PANSS positive subscale were -10.81 
(standard deviation [SD], 3.31) for the PPLAI-1M group and -6.56 
(SD, 5.82) for the oral treatment group. As observed in Table 2, 
patients in the PPLAI-1M group showed better improvement in 
reducing the PANSS total score than those in the oral treatment 
group (P  <  .001). This improvement was also observed in the 
PPLAI-3M group, in which general maintenance of psychopatho-
logical stability was observed over time. It is worth noting that 
prior to starting PPLAI-3M treatment, patients must be clinically 
stabilized for at least 4 months at the same dosage of PPLAI-1M.
Figure 1. Description of the sample selection from the CRUPEP first-episode psychosis cohort. Abbreviation: CRUPEP, First Episode Psychosis Intervention Program; FEP, 














 user on 22 D
ecem
ber 2021
Copyedited by:  
Segarra et al. | 697
CGI-I and CGI-S—During the 12-month study period, the 
severity of symptoms measured by the CGI-S scale significantly 
decreased in both the oral risperidone/paliperidone and PPLAI-
1M groups (z = -4.63; P < .001). Similarly, scores on the CGI-I scale 
registered improvement both in the oral and PPLAI-1M patients 
(U = 48.50; P = .002).
As shown in Table 2, patients in the PPLAI-1M group pre-
sented higher basal severity scores on the CGI-S scale compared 
to those in the oral group (P  =  .002). At the final assessment, 
patients in the PPLAI-1M group reached similar CGI-S scale re-
sults compared with patients taking oral antipsychotics. Despite 
that, the PPLAI-1M group obtained better improvement in the 
symptom severity scale, with a mean change from baseline of 
-2.37 (SD, 1.09) compared to -1.37 (SD, 1.54) in the oral arm. As 
observed in Figure 2, at the final assessment, patients in the 
PPLAI-3M group showed significant improvements in CGI-S 
and CGI-I scores compared to those in the oral group (z = 2.84; 
P = .004) and PPLAI-1M group (z = 3.55; P < .001).
PSP Scale—There were no statistical differences in PSP scores at 
baseline between groups. During the 12-month follow-up period, 
patients’ functioning measured through the PSP improved 
significantly from baseline to the endpoint in both the oral and 
PPLAI-1M treatment groups (t [31] = -6.89; P < .001). Despite that, 
as observed in Table 2, patients in the PPLAI-1M group showed 
significantly greater improvement in the PSP scale score, with a 
mean change from baseline to the endpoint of 16.62 (SD, 9.64).
Comparatively, patients receiving PPLAI-3M obtained greater 
PSP score results than those reported in the oral treatment 
group (t[31] = -2.24; P = .032). When compared with patients in 
Table 2. Change in clinical and functional scales from baseline to endpoint in the oral and paliperidone palmitate long-acting inject-
able 1-month and 3-month treatment groups
Oral risperidone or paliperidone, n = 16
Paliperidone palmitate  
1M, n = 16
Paliperidone palmitate  
3M, n = 16 P value
PANSS positive subscale, mean (SD)
 Baseline 14.69 (4.70) 18.19 (3.76) 7.56 (1.55) .006
 Change from baseline -6.56 (5.82) -10.81 (3.31) -0.38 (1.26)
PANSS negative subscale, mean (SD)
 Baseline 7.63 (1.41) 8.94 (2.02) 8.44 (1.83) NS
 Change from baseline 1.87 (3.90) 0.00 (3.05) 0.19 (2.26)
PANSS general subscale, mean (SD)
 Baseline 23.88 (4.03) 25.00 (2.76) 17.63 (2.71) <.001
 Change from baseline -5.56 (4.02) -5.69 (3.36) 0.25 (1.95)
PANSS total score, mean (SD)
 Baseline 46.19 (4.87) 52.44 (4.87) 34.63 (5.38) <.001
 Change from baseline -10.25 (8.60) -16.81 (5.56) -1.06 (4.14)
CGI-S, mean (SD)
 Baseline 4.06 (0.77) 5.13 (0.89) 2.50 (0.632) <.001
 Change from baseline -1.37 (1.54) -2.37 (1.09) -0.06 (0.25)
PSP score, mean (SD)
 Baseline 62.69 (10.47) 56.38 (7.65) 70.56 (6.90) <.001
 Change from baseline 7.19 (7.56) 16.62 (9.64) 7.56 (5.45)
Abbreviations: 1M, 1-month dose; 3M, 3-month dose; CGI-S, Clinical Global Impression Severity; PANSS, Positive and Negative Syndrome Scale; PSP, Personal and Social 
Performance Scale; NS, not significant; SD, standard deviation.
Table 1. Sociodemographic and clinical characteristics of patients receiving palmitate paliperidone long-acting injectable formulations or oral 
risperidone or paliperidone antipsychotics
Oral risperidone 
or paliperidone  
(n = 16)
Paliperidone 
palmitate 1M  
(n = 16)
Paliperidone  
palmitate 3M  
(n = 16) P value
Age, in years, mean (SD) 39.8 (9.89) 29.6 (9.67) 35.8 (6.67) <.05
DUP, in weeks, mean (SD) 16.4 (13.9) 17.5 (20.1) 15.8 (12.3) .991
Sex – male, n (%) 8 (50) 13 (81) 13 (81) .080
Marital status – single, n (%) 11 (69) 10 (62.5) 10 (62.5) .775
Living environment - family of origin, n (%) 9 (56) 12 (75) 7 (44) .189
Laboral status – unemployed, n (%) 8 (50) 11 (69) 11 (69) .449
Education level – secondary education, n 
(%)
11 (69) 14 (78) 12 (75) .376
Main psychiatric diagnose – schizophrenia, 
n (%)
12 (75) 14 (87.5) 15 (94) .310
Drug abuse – yes, n (%) 7 (44) 12 (75) 9 (56) .196
Family psychiatric history, n (%) 6 (37.5) 7 (43.8) 5 (31.3) .766
Antipsychotic monotherapy, n (%) 16 (100) 16 (100) 16 (100)  
Concomitant medication – 
benzodiazepines, n (%)
13 (81) 15 (94) 5 (31) <.001
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the PPLAI-1M group, those in the PPLAI-3M had a statistically 
significant difference in PSP scores (t [31] = -4.689; P < .001) and 
a better level of functioning at the final assessment (Figure 3).
Health Resources Use—At baseline, 31 patients (64%) had a history 
of at least 1 psychiatric hospitalization before risperidone/
paliperidone initiation. Comparatively, the PPLAI-1M group 
had a higher rate of the previous hospitalizations compared 
to other groups, which was statistically significant (44% oral; 
94% PPLAI-1M; 56% PPLAI-3M; P  =  .009). During the 12-month 
follow-up, 3 (18%) patients in the oral group, 1 (6%) in the PPLAI-
1M group, and 1 (6%) in the PPLAI-3M group were hospitalized. 
We did not find a statistically significant difference between 
groups (P =  .409). The main reason for hospitalization was the 
inadequate management of clinical symptoms. None of the 
hospitalizations were due to severe adverse drug reactions. 
Concerning emergency room attendance, 3 patients in the oral 
group, 2 patients in the PPLAI-1M group, and 1 patient in the 
PPLAI-3M group required at least 1 visit to the emergency room 
during the 1-year study follow-up (P = .565).
Dosage—As shown in Table 1, all patients were on antipsychotic 
monotherapy. As a part of our FEP-CRUPEP Program, most 
patients were in treatment with low doses of oral antipsychotics, 
with baseline mean doses of 4.33 mg daily for oral paliperidone 
(n = 10; SD, 2.18 mg/day dosage range, 3–9 mg/day) and 3.50 mg 
daily for oral risperidone (n = 6; SD, 1.38 mg/day; dosage range, 
2–4 mg/day). It should be mentioned that only 1 of the patients 
was on treatment with oral paliperidone at 9  mg/day due to 
clinical criteria. At the baseline assessment, the doses in patients 
from the PPLAI-1M group ranged from 75 mg to 150 mg, with a 
mean dose of 123.44 mg (SD, 28.09 mg). Finally, patients in the 
PPLAI-3M group were prescribed a mean dose of 328.19 mg (SD, 
121.63) at baseline, with doses ranging from 175 mg to 525 mg. 
The main initiation doses of all patients receiving PPLAI after 



























Figure 2. Changes between groups in CGI-S score from baseline to final assessment. Abbreviations: CGI-S, Clinical Global Impression–Severity of illness; Oral, oral 
risperidone or paliperidone antipsychotics; PPLAI-1M, paliperidone palmitate long-acting injectable 1-month dose; PPLAI-3M, paliperidone palmitate long-acting in-
jectable 3-month dose; SD, standard deviation.





















Figure 3. Mean changes between groups in PSP score from baseline to endpoint. Abbreviations: Oral, oral risperidone or paliperidone antipsychotics; PPLAI-1M, 
paliperidone palmitate long-acting injectable 1-month dose; PPLAI-3M, paliperidone palmitate long-acting injectable 3-month dose; PSP, Personal and Social Perform-
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At the final assessment, 21 patients (43.8%) reported a re-
duction of their initial antipsychotic dose and only 3 patients 
(6%)—2 in the oral group and 1 in the PPLAI-1M group—ex-
perienced a dose increase. At the endpoint, patients in the 
oral group received mean oral doses of 4.68 mg paliperidone 
(n = 10; SD, 2.18 mg/day; dosage range, 3–9 mg/day) and 2 mg 
risperidone (n = 6; SD, 0.75 mg/day; dosage range, 1–3 mg/day). 
Additionally, a reduction in the median dose was observed in 
the PPLAI-1M group (mean dose, 85.94 mg; SD, 34.12 mg; dosage 
range, 25–150 mg). Conversely, although a reduction of the anti-
psychotic dose was observed in the LAIPP-3M group, patients 
received a mean dose of 311.88  mg (SD, 123.55  mg; dosage 
range, 175–350  mg). Finally, patients in the PPLAI-1M group 
had a significant progressive reduction of the dose (z = -2.516; 
P  =  .112). Overall, a reduction in the standard doses of anti-
psychotics for all groups was observed across the study period 
(Figure 4). The low concomitant use of benzodiazepines in all 
groups, and mainly in the PPLAI-3M group, is also notable, as 
shown in Table 1.
Side effects—Treatment side effects were reported in 12 patients 
(24%), with the most described side effects related to sedation 
(42%), sexual dysfunction (40%), and weight gain (25%). In 
general, there were no statistical differences between groups, 
despite the PPLAI-1M group more frequently reporting an 
increased percentage of side effects, with the most prevalent 
being weight gain (25% oral; 33.3% PPLAI-1M; 12.5% PPLAI-3M, 
P = .363).
Discussion
To our knowledge, this is the first study assessing the use of 
palmitate paliperidone long-acting 1- or 3-month formula-
tions versus oral risperidone or paliperidone in a sample of 
patients with FEP. The results of our retrospective study show 
that both oral paliperidone or risperidone and PPLAI formula-
tions are effective not only in the treatment of clinical symp-
toms but also in maintaining those improvements throughout 
at least 12 months. Despite that, there are some relevant dif-
ferences between the 3 pharmacological groups that must be 
considered.
First, all patients seemed to achieve significant remission of 
clinical symptoms assessed through the PANSS scale. Despite 
that, it is necessary to consider that due to inner characteris-
tics of the PPLAI-1M sample, patients in this group presented a 
higher baseline PANSS positive score. These results should be 
understood considering our study’s real-world setting, where 
patients in the PPLAI groups are often those who present with 
major clinical severity and treatment nonadherence. Thus, they 
could benefit from long-acting formulations to prevent lack of 
treatment adherence and consequent relapses.
Likewise, patients in both the PPLAI-1M and PPLAI-3M groups 
compared to those the oral treatment arm achieved significant 
improvements in all scales evaluated. Therefore, and due to 
the lack of studies assessing the efficacy of such formulations 
in patients with an FEP in a real-world setting, we tried to test 
whether patients in the PPLAI-3M group maintained clinical sta-
bility throughout 12 months of follow-up.
As a result, patients in the PPLAI-3M group obtained even 
better scores for general clinical symptom severity and saw a 
substantial improvement in the main domains of personal and 
social functioning, assessed through the PSP scale. Our data are 
consistent with those of previous studies reported in the litera-
ture, where PPLAI-3M formulation is recommended after clin-
ical stability on PPLAI-1M for a minimum of 4 months (European 
Medicines Agency, 2016; Taylor and Huang, 2017). These re-
sults may be of particular relevance beyond the remission of 
acute symptoms, as functional recovery remains 1 of the main 
therapeutic goals to be achieved and involves patients’ overall 
day-to-day functioning, with particular importance for their 
long-term global prognosis after FEP onset (Álvarez-Jiménez 
et al., 2012a; Santesteban-Echarri et al., 2017).
We did not find statistically significant differences for either 
admissions or attendances at psychiatric emergency depart-
ments among groups. Despite that, out of the total number of 
people requiring psychiatric admission, 60% were in the oral 
treatment group. Moreover, considering that all patients in-
cluded in the CRUPEP Program are monitored from the debut of 
their disease, this close protocolized follow-up could influence 
and contribute to lower rates of additional health resources use. 
As mentioned previously, the main reason for hospitalization 
was inadequate management of clinical symptoms. Thus, the 
prescribed doses of antipsychotics were adjusted according to 
clinical criteria.
It is noteworthy that more than 60% of the sample were 
antipsychotic-naïve patients, and all of them were on anti-
psychotic monotherapy at lower doses than those usually re-
ported in the literature. This is our current clinical practice, 
according to the pharmacotherapeutic rationale intervention 
philosophy adopted in our FEP-CRUPEP Program.
As stated above, a trend towards reducing the antipsychotic 
dose is observed, to use the minimum effective dose to avoid 
the occurrence of unwanted side effects (Dixon and Stroup, 
2015; Crespo-Facorro et  al., 2016). Benzodiazepine adminis-
tration is also exceptional and, if prescribed, benzodiazep-
ines are sustained during a brief lapse of time according to a 
descendant dosage strategy (with a maximum of 12 weeks). 
A  significant reduction of benzodiazepine use was observed 
in the LAIPP-3M group due to psychopathological stability and 
patients’ clinical improvements. We assume that the main 
reason for this result is derived from better and sustained clin-
ical and functional outcomes, mainly in the PPLAI-3M group, 
which was able to reduce the anxiety levels derived from ab-
normal, psychotic experiences and difficulties in managing 
daily life events.
Despite the lack of literature regarding the effectiveness of 
long-acting antipsychotic formulations in patients with an FEP, 
our results are in line with those reporting the effectiveness 
of PPLAI-1M and PPLAI-3M formulations on the treatment of 
patients with early-onset psychosis (Emsley et  al., 2008, 2017; 
Zhang et al., 2015; Bossie et al., 2017; Petrić et al., 2019).
Another handicap present in literature concerns the vast 
majority of published studies only considering patients with 
chronic schizophrenia. Only a few of them analyze the ef-
fectiveness of new antipsychotic formulations, including LAI 
Table 3. Initiation dose strategy of all included patients on 
paliperidone palmitate depot formulations (n = 32) switching from 
oral risperidone or paliperidone to a 1-month dose of injectable 
paliperidone palmitate
Initiation dose
Maintenance dose n (%)Day 1 Day 8
150 mg 100 mg 150 mg 10 (31.3)
100 mg 100 mg 100 mg 20 (62.5)
100 mg 75 mg 75 mg 1 (3.1)
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formulations, in recent-onset psychosis and FEPs. Indeed, our 
research group has recently published a systematic review of the 
use of second-generation long-acting antipsychotics (LAI-SGA) 
in patients with an FEP. Among the main results, we conclude 
that treatment with LAI-SGAs could offer several advantages 
over oral treatment in FEPs, such as treatment adherence and 
relapse prevention due to treatment discontinuation (Salgueiro 
and Segarra, 2019).
Accordingly, we present here the first study assessing the use 
of PPLAI formulations, in 1-month or 3-month doses, versus oral 
risperidone or paliperidone in an FEP sample, trying to confirm 
our former hypothesis empirically.
As previously mentioned, due to the particularities of daily 
clinical practice, patients in the PPLAI-1M group frequently had 
more severe symptoms, presenting lack of insight, treatment 
nonadherence, and substance use. Treatment noncompliance 
remains a key issue in patients with schizophrenia. Thus, 
long-acting formulations seem to present a therapeutic option 
for those patients that present with an increased risk of treat-
ment discontinuation and relapse (Kane and Garcia-Ribera, 
2009; Arango et  al., 2019). Moreover, including PPLAI formula-
tions seems to be an effective therapeutic choice for treating 
clinical symptoms and improving the psychosocial burden of 
the disease, even in the early stages an FEP, in patients that vol-
untarily accept and consider such a therapeutical option after 
giving adequate informed consent. LAI treatment has emerged 
as an alternative to oral formulations to improve treatment ad-
herence and reduce the risk of relapse and, thus, chronic states 
of the disease (Fagiolini et al., 2017). Despite that, and consid-
ering the potential therapeutic benefits of these formulations, 
the rate of LAI prescribing remains low (Arango et al., 2019).
Our study has several limitations. First of all, the sample 
size is small, which limits the generalization of the results. The 
study is a retrospective, observational study designed to ex-
plore treatment outcomes and is limited by criteria selection. 
Due to the inclusion criteria, patients were required to have 
been on treatment with an oral antipsychotic (risperidone or 
paliperidone) or with a PPLAI 1-month or 3-month formulation 
for at least 12  months; therefore, there could be bias among 
groups, as patients using LAI formulations are adherent to anti-
psychotic treatment, while real adherence to oral antipsychotic 
treatment is unknown. In this regard, our research group re-
cently published a study testing plasmatic blood concentra-
tions of the main oral second-generation antipsychotics in 
an FEP sample, pointing out that nearly half of the enrolled 
patients were nonadherent to oral antipsychotic treatment or 
presented subtherapeutic levels at 1 year of follow-up (Bustillo 
et al., 2018). Additionally, as discussed above, the close clinical 
monitoring of all patients included in our FEP program may 
have resulted in lower hospitalization rates and less clinical 
resource use. Considering these limitations, the outcomes of 
this study are in need of further confirmation due to the lack 
of studies addressing the use of LAI formulations in patients 
with an FEP.
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